摘要
目的探讨不同剂量重组人促红细胞生成素(rhEPO)治疗早产儿脑损伤的疗效与安全性。方法收集焦作市妇幼保健院2015年4月—2016年4月收治的脑损伤早产儿156例。随机分为rhEPO大剂量、中剂量、小剂量治疗组各52例。测量3组患者治疗前后血浆超氧化物歧化酶(SOD)、中枢神级特异性蛋白(S100B)、人促红细胞生成素(EPO)水平,于纠正胎龄40周时采用新生儿神经行为测定评分法(NBNA)评估患儿神级系统功能恢复情况。结果与治疗前比较,各组治疗后血浆IL-6、S100B水平明显降低,血浆EPO水平明显升高(P<0.05);低剂量组、中剂量组、高剂量组治疗后血浆IL-6、S100B水平顺序降低,血浆EPO水平顺序升高(P<0.05);低剂量组、中剂量组、高剂量组纠正胎龄40w时NBNA评分逐渐升高(P<0.05)。结论重组人促红细胞生成素能通过降低血浆IL-6、S100B水平发挥脑细胞修复作用,高剂量rh EPO治疗早产儿脑损伤的疗效更佳,且未见明显不良反应,安全性高。
Objective To discuss the curative effects and safety of different doses of rhEPO treating premature brain injury. Methods Totally 156 cases of premature brain injury admitted and treated in our hospital during April 2015 and April 2016 were randomly divided into rh EPO large dose group,rhEPO medium dose group and rhEPO small dose group with each group 52 cases. Test the patient ＇ SOD,S100B,EPO levels of before and after treatment among the three groups. Adopt the NBNA to evaluate the rehabilitation condition of the patients＇ neurological function at the correct gestational age of 40 weeks. Results Comparing with those before treatment,the plasma IL-6,S100B levels of after treatment in the three groups were significantly more decreased,while the plasma EPO level was significantly more increased（ P〈 0. 05）. After treatment,the plasma IL-6 and S100B levels were sequentially decreased from small dose group,medium dose group and large dose group,while the plasma EPO level was sequentially increased from small dose group,medium dose group and large dose group（ P〈 0. 05）. The NBNA scores at the correct gestational age of 40 weeks were sequentially increased from small dose group,medium dose group and large dose group（ P〈 0. 05）. Conclusion rhEPO can repair the brain cells through decreasing the plasma IL-6 and S100B levels. Large dose of rhEPO is proved to have the best curative effects in treating premature brain injury,with no clear adverse reaction and high safety.
出处
《医药论坛杂志》
2018年第1期76-77,80,共3页
Journal of Medical Forum
